12
Views
6
CrossRef citations to date
0
Altmetric
Miscellaneous Article

The Off-Label Debate: A Threat to the Future of Cancer Care

Pages 597-599 | Published online: 11 Jun 2009

References

  • Mortenson L. E. Audit indicates half of current chemotherapy uses lack FDA approval. J Cancer Program Mgmt 1988; 3(1)21–25
  • Mortenson L. E. Audit indicates many uses of combination therapy are unlabeled. J Cancer Program Mgmt 1988; 3(1)33
  • Yarbro W., Mortenson L. E. The need for DRG 471 — protection for clinical research. J Am Med Assoc 1985; 253(5)684–685
  • Davis C. The impact of prospective payment on clinical research progress. J Am Med Assoc 1985; 253(5)686–687

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.